Acute Liver Failure Market: Analysis of Epidemiology, Pipeline Therapies and Key Companies Working in the Market

[ad_1]

DelveInsight Business Research LLP

DelveInsight’s “Acute Liver Failure Market Insights, Epidemiology, and Market Forecast-2032” report provides an in-depth understanding of Acute Liver Failure, historical and forecasted epidemiology, and market trends of Acute Liver Failure in United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

by DelveInsight”Acute Liver Failure Market Overview, Epidemiology and Market Forecast-2032″ The report provides an in-depth understanding of Acute Liver Failure, historical and forecasted epidemiology, and market trends of Acute Liver Failure in the United States, EU5 (Germany, Spain, Italy, France and UK) and Japan.

The Acute Liver Failure Market report provides current treatment practices, emerging drugs, Acute Liver Failure market share of individual therapies, current and forecasted Acute Liver Failure market size of 2019 to 2032 segmented by seven main markets. The report also covers current Acute Liver Failure treatment practices/algorithms, market drivers, market barriers and unmet medical needs to select the best opportunities and assesses the underlying potential of the market for acute liver failure.

Some of the main facts of the Live acuteuh Chess Market Report:

  • In the study by Sato et al. (2014), a total of 1554 and 49 patients with ALF and late liver failure (LOHF), respectively, meeting the Japanese diagnostic criteria, who were seen between 2010 and 2015 were recruited. The subjects were classified into 1280 patients with hepatitis (642 non-comatose and 638 comatose) and 323 patients without hepatitis (190 non-comatose and 133 comatose). Compared to patients seen between 1998 and 2009, an older patient age and a higher percentage of underlying extrahepatic disease were observed.

  • In the same study, although hepatitis virus infection was the most common etiology, the percentage of patients with this etiology had decreased compared to previous cohorts, while the percentages of patients with lesions drug-induced hepatic, autoimmune hepatitis and undetermined etiology increased. Liver transplantation was performed in 170 patients (10.6%), while artificial liver support with plasmapheresis and/or haemodiafiltration was performed for most comatose patients.

Key Benefits of Acute Liver Failure Report:

  • The report covers the descriptive overview of Acute Liver Failure, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies.

  • A comprehensive overview was provided on the epidemiology and treatment of acute liver failure in 7MM.

  • Additionally, a comprehensive account of current and emerging therapies for acute liver failure is provided, along with the assessment of new therapies, which will impact the current treatment landscape.

  • A Detailed Review of the Acute Liver Failure Market; historical and forecast is included in the report, covering drug awareness in 7MM.

You have questions ? Click here to learn more about the Acute Liver Failure Market Landscape

Overview of Acute Liver Failure

Acute liver failure (ALF) is the development of sudden and severe liver dysfunction following acute liver injury, associated with the onset of hepatic encephalopathy and coagulation abnormalities. The American Association for the Study of Liver Diseases (AASLD) defines it as evidence of a coagulation abnormality, usually an international normalized ratio greater than 1.5, and any degree of mental impairment (encephalopathy) in a patient without pre-existing liver disease and with less disease duration greater than 26 weeks.

The disease often begins with nonspecific symptoms, including malaise, fatigue, nausea, and abdominal pain. Jaundice (yellowing of the skin) and scleral jaundice (yellowing of the eyes) are often present, but may not initially be noticed by patients or their families until relatively late in the course of the disease. Encephalopathy, the cognitive dysfunction that is a sine qua non of ALF, can also initially be quite subtle. Minor personality changes, especially irritability, inattentiveness, mild memory lapses, and insomnia may be the first signs. However, the severity of the encephalopathy can worsen dramatically and suddenly, culminating in complete hepatic coma in a relatively short time.

Diagnosis of ALF involves obtaining detailed and accurate historical information, performing a physical examination of the patient focused primarily on determining the stage of the encephalopathy, excluding stigmata of liver disease chronic, and looking for clues regarding the etiology of ALF (eg, Kaiser-Fleisher rings in Wilson’s disease), undergoing extensive blood and urine tests both to assess severity liver failure and to determine the etiology.

Additionally, an abdominal ultrasound is done to assess the size, configuration, and texture of the liver, to verify that its vascular supply is intact, and to rule out masses or other problems. of ALF helps in the management of the disease. For drug-induced hepatotoxicity, intravenous N-acetylcysteine ​​(NAC) is used, while patients with acute hepatitis B-induced ALF benefit from antiviral agents, while osmotic agents such as mannitol are the first-line treatment for raised intracranial pressure in patients with ALF. Liver transplantation improved survival in ALF.

Epidemiological overview of acute liver failure:

  • In the study by Stravitz and Lee (2019), data was collected between January 1, 1998 and March 31, 2019. PubMed and MEDLINE using the terms “acute liver failure” or “fulminant liver failure” were searched, for identify studies and publications that are not already known to the authors, without restriction as to date or place of publication. The total number of patients enrolled was 2614; paracetamol accounted for 46% of cases, 12% of cases had undetermined causes, and drug-induced liver injury accounted for 11% of cases.

  • According to the above study by Stravitz and Lee (2019), the most commonly observed cause of ALF in developed countries is paracetamol toxicity, which causes 45.7% of recorded cases in North America and 65, 4% of cases in the UK. . 80% of patients with ALF caused by autoimmune hepatitis are women. In the United States and Europe, the hepatitis B virus causes approximately 8% of all cases of ALF, considerably less than paracetamol, drug-induced liver injury or autoimmune hepatitis, but this virus remains an important and easily diagnosed cause. Other causes of ALF account for less than 15% of the total and include heatstroke, pregnancy-associated injuries (eg, acute fatty liver of pregnancy, and HELLP [hemolysis, elevated liver enzyme, and low platelet] syndrome), Budd-Chiari syndrome, non-hepatotropic viral infections such as herpes simplex and diffuse infiltrating malignancies.

  • In the study by Weiler et al. (2020), insured patients from January 2014 to December 2018 in Germany were analyzed and the incidence of ALF was calculated as 1.13/100000 person-years, which represents 4652 cases. Health care data from approximately 25 million people to the total population of 83 million were extrapolated. Women were found to be affected more often (52% versus 48%).

Epidemiological segmentation of acute liver failure

  • Total incident cases of acute liver failure

  • Total number of acute liver failure cases by gender

  • Specific cases of the etiology of acute total liver failure

  • Total number of acute liver failure cases by age

  • Total number of treated cases of acute liver failure

Acute Liver Failure Market Outlook

The report’s Acute Liver Failure market outlook helps construct a detailed understanding of the historical, current, and forecasted Acute Liver Failure market trends by analyzing the impact of current Acute Liver Failure therapies on the market , unmet needs, drivers and barriers, and demand. for better technology.

This segment gives a comprehensive detail of Acute Liver Failure market trend of each marketed drug and late-stage pipeline treatment by rating their impact based on annual treatment cost, inclusion and exclusion criteria, mechanism of action, rate of compliance, growing market need, increasing number of patients, patient segment covered, expected launch year, competition with other therapies, value of the brand, their impact on the market and the opinion of key opinion leaders. The calculated data of Acute Liver Failure market is presented with relevant tables and graphs to give a clear view of the market at first glance.

According to DelveInsight, the acute liver failure in 7MM market is expected to see a major shift during the study period 2019-2032.

Learn more by requesting a sample @ Acute Liver Failure Market Trends

Leading Acute Liver Failure Companies

  • Akaza Biosciences

  • Griffols

  • Mallinckrodt

  • And others

Treatments for acute liver failure

  • Resatorvid (TAK-242)

  • And others

Contents

  1. key ideas

  2. Presentation of the report

  3. Executive Summary of Acute Liver Failure

  4. Background and overview of the disease

  5. Epidemiology and patient population

  6. Acute Liver Failure Emerging Therapies

  7. Acute Liver Failure Market Outlook

  8. Market access and reimbursement of therapies

  9. Annex

  10. Acute Liver Failure Reporting Methodology

  11. Features of DelveInsight

  12. Disclaimer

  13. About DelveInsight

Click here to read more about Acute Liver Failure Market Analysis

Media Contact
Company Name: DelveInsight Business Research
Contact person: Adya Kaoul
E-mail: Send an email
Call: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
Town: Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com

[ad_2]
Source link

Comments are closed.